New executives appointed! Jiangsu Hengrui Pharmaceuticals appoints a new president, aiming to strengthen internationalization?|Quick announcement summary

① Feng Ji, who has worked for AstraZeneca for many years, has officially been appointed as the President and Chief Operating Officer of Jiangsu Hengrui Pharmaceuticals. ② According to industry insiders, the current executive team at Hengrui remains stable, with no significant changes in the roles of other major executives. ③ Industry insiders believe that Jiangsu Hengrui Pharmaceuticals values Feng Ji's experience in multinational pharmaceutical companies.

cls.cnApr 2 09:11 ET

The entire pharmaceutical sector has surged sharply; what happened?

On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.

wallstreetcnApr 1 08:38 ET

Introducing two major international capitals, Fosun UnitedHealth is starting a new round of capital increase and share expansion, and after multiple rounds of financing, it will focus on the Fosun ecosystem.

① Planning to introduce two major international capitals: the International Finance Corporation and the Asian Development Bank; ② The total cash investment from investors amounts to 0.81 billion yuan (or the equivalent in USD); ③ Since its establishment, multiple rounds of funding have been obtained through shareholder donations and capital increases.

cls.cnApr 1 08:26 ET

The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?

Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.

cls.cnApr 1 00:04 ET

In 2024, Jiangsu Hengrui Pharmaceuticals achieved record high revenue and net profit, with explosive growth in Innovative Drugs and research and development investment accounting for nearly 30% of revenue | Earnings Reports insights.

Net income is 6.337 billion yuan, a sharp increase of 47.28% year-on-year. Innovative Drugs sales reached 13.892 billion yuan, a year-on-year growth of 30.60%, accounting for nearly 50% of total revenue, becoming the core engine for performance growth.

wallstreetcnMar 30 07:54 ET

The Social Security Fund's annual report on Hold Positions has been revealed! A total of 52 new stocks entered the top ten circulating Shareholders list, with China Resources Double-Crane Pharmaceutical receiving the most Shareholding increases.

① With the continuous disclosure of the 2024 annual reports of listed companies, the Social Security Fund has newly entered the top ten circulating shareholders list of 52 individual stocks; ② Among them, China Resources Double-Crane Pharmaceutical has the highest number of new holdings by the Social Security Fund, reaching 3; ③ Attached is the list of A-shares where the number of newly added Institutions held by the Social Security Fund in the fourth quarter of 2024 ranks highest (attached table).

cls.cnMar 29 04:55 ET